Clinical sequencing startup Parabase Genomics announced this month that it is developing a targeted sequencing test for neonates suspected to be suffering from genetic diseases.
Parabase's CEO Andy Bhattacharjee discussed the company's plans for what it calls the Lifetime test at the Consumer Genetics Conference earlier this month.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
